[go: up one dir, main page]

EE200300213A - SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks - Google Patents

SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks

Info

Publication number
EE200300213A
EE200300213A EEP200300213A EEP200300213A EE200300213A EE 200300213 A EE200300213 A EE 200300213A EE P200300213 A EEP200300213 A EE P200300213A EE P200300213 A EEP200300213 A EE P200300213A EE 200300213 A EE200300213 A EE 200300213A
Authority
EE
Estonia
Prior art keywords
sarp
scleroderma
prevention
treatment
medicament
Prior art date
Application number
EEP200300213A
Other languages
English (en)
Inventor
Plater-Zyberk Christine
Power Christine
Colinge Jacques
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200300213A publication Critical patent/EE200300213A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
EEP200300213A 2000-12-06 2001-11-30 SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks EE200300213A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17
PCT/EP2001/013992 WO2002046225A2 (en) 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or prevention of scleroderma

Publications (1)

Publication Number Publication Date
EE200300213A true EE200300213A (et) 2003-08-15

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300213A EE200300213A (et) 2000-12-06 2001-11-30 SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks

Country Status (29)

Country Link
US (2) US7341995B2 (et)
EP (2) EP1806144A3 (et)
JP (1) JP2004525869A (et)
KR (1) KR100804885B1 (et)
CN (1) CN1323716C (et)
AT (1) ATE359808T1 (et)
AU (2) AU2002226366B2 (et)
BG (1) BG107941A (et)
BR (1) BR0115983A (et)
CA (1) CA2428092A1 (et)
CY (1) CY1107687T1 (et)
CZ (1) CZ20031855A3 (et)
DE (1) DE60128009T2 (et)
DK (1) DK1411970T3 (et)
EA (1) EA005973B1 (et)
EE (1) EE200300213A (et)
ES (1) ES2281463T3 (et)
HR (1) HRP20030426A2 (et)
HU (1) HUP0302738A3 (et)
IL (1) IL156069A0 (et)
MX (1) MXPA03005027A (et)
NO (1) NO20032597L (et)
NZ (1) NZ525774A (et)
PL (1) PL365316A1 (et)
PT (1) PT1411970E (et)
SK (1) SK8472003A3 (et)
UA (1) UA83790C2 (et)
WO (1) WO2002046225A2 (et)
YU (1) YU45103A (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69726884T2 (de) * 1997-02-06 2004-06-03 Genetics Institute, LLC, Cambridge Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
KR20040107492A (ko) * 2002-04-10 2004-12-20 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 섬유증 질병의 치료 및/또는 예방을 위한오스테오프로테게린의 용도
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
AU2006213875B2 (en) * 2005-02-08 2010-08-19 Genzyme Corporation Antibodies to TGFBETA
JP5025646B2 (ja) * 2005-11-08 2012-09-12 公益財団法人先端医療振興財団 虚血性心疾患の治療方法
AU2008334608A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. SARP-1 fusion proteins and uses thereof
EP3025715A1 (en) * 2011-03-11 2016-06-01 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
WO2022217037A1 (en) 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Compositions and methods for treatment of chronic lung diseases
CN117756910A (zh) * 2023-12-22 2024-03-26 首都医科大学附属北京口腔医院 Sfrp2功能多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
DE69735375T3 (de) 1996-09-24 2010-09-02 Tanox, Inc., Houston Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
DE69726884T2 (de) * 1997-02-06 2004-06-03 Genetics Institute, LLC, Cambridge Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses

Also Published As

Publication number Publication date
CN1323716C (zh) 2007-07-04
DE60128009T2 (de) 2007-08-23
AU2002226366B2 (en) 2007-03-22
IL156069A0 (en) 2003-12-23
US20080107627A1 (en) 2008-05-08
ATE359808T1 (de) 2007-05-15
KR100804885B1 (ko) 2008-02-20
CY1107687T1 (el) 2012-05-23
BG107941A (bg) 2004-01-30
US7655628B2 (en) 2010-02-02
ES2281463T3 (es) 2007-10-01
UA83790C2 (ru) 2008-08-26
HUP0302738A3 (en) 2010-01-28
EA200300639A1 (ru) 2003-12-25
EP1411970A2 (en) 2004-04-28
US7341995B2 (en) 2008-03-11
EP1411970B1 (en) 2007-04-18
DE60128009D1 (de) 2007-05-31
EA005973B1 (ru) 2005-08-25
NO20032597D0 (no) 2003-06-06
PL365316A1 (en) 2004-12-27
CA2428092A1 (en) 2002-06-13
EP1806144A3 (en) 2008-04-23
SK8472003A3 (en) 2003-10-07
HUP0302738A2 (hu) 2003-11-28
DK1411970T3 (da) 2007-06-04
PT1411970E (pt) 2007-05-31
MXPA03005027A (es) 2003-09-05
CN1553806A (zh) 2004-12-08
YU45103A (sh) 2006-08-17
KR20030076585A (ko) 2003-09-26
NO20032597L (no) 2003-06-06
WO2002046225A3 (en) 2004-01-08
JP2004525869A (ja) 2004-08-26
HRP20030426A2 (en) 2005-04-30
WO2002046225A2 (en) 2002-06-13
HK1068106A1 (zh) 2005-04-22
CZ20031855A3 (cs) 2003-09-17
EP1806144A2 (en) 2007-07-11
AU2636602A (en) 2002-06-18
US20050113291A1 (en) 2005-05-26
NZ525774A (en) 2006-03-31
BR0115983A (pt) 2003-12-30

Similar Documents

Publication Publication Date Title
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
GB9907461D0 (en) Neurite regeneration
MXPA03005731A (es) Articulo absorbente que tiene tratamientos medicinales liberables.
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
SE9904377D0 (sv) Pharmaceutical combinations
CY1107687T1 (el) Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
DK1352658T3 (da) Forebyggelse eller lægemiddel mod endometriose
ATE374203T1 (de) Therapeutische verbindungen und verfahren
BR0111785A (pt) Composições e métodos para tratamento de candidìase
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
DE60124516D1 (de) Kombination des lezithins mit ascorbinsäure
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
BR0211522A (pt) Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
ZA200304519B (en) Absorbent article having releasable medicinal treatments.

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner